Holen Sie sich die Stockscreener-App
16.66
0.77%
-0.13
Handel nachbörslich:
16.66
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history - Yahoo Finance Singapore
Form 13D/A ArriVent BioPharma For: 8 October By Investing.com - Investing.com India
Form 13D/A ArriVent BioPharma For: 8 October By Investing.com - Investing.com Canada
BTIG cuts ArriVent BioPharma stock price target on trial results - Investing.com
Chinese biotech faces reality check as ArriVent drug failure sinks stock in US - South China Morning Post
Avbp stock hits 52-week low at 12.09 USD - Investing.com
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) - PR Newswire
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low - AOL.com
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings - Benzinga
Why ArriVent BioPharma (AVBP) Stock Is Down Today - Quiver Quantitative
Why ArriVent BioPharma (AVBP) Stock Is Down Today - Quiver Quantitative
There are notable gap-ups and gap-downs in today's session. - ChartMill
ArriVent stock plunges on cancer trial failure (AVBP:NASDAQ) - Seeking Alpha
AVBP Stock Holds Range As Cash-Rich Biotech Plans Next Move - Timothy Sykes
AVBP Stock Holds Range As Cash-Rich Biotech Plans Next Move - Timothy Sykes
AVBP Slips 2.28% as ArriVent BioPharma Tests Support Near $26.86Runaway Gap - https://www.siam.in/
AVBP Slips 2.28% as ArriVent BioPharma Tests Support Near $26.86Volatility Breakout Picks - https://www.dars.gov.et/
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study - TipRanks
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP) - Seeking Alpha
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - qz.com
Why Did ArriVent BioPharma (AVBP) Move Today? - Simply Wall Street
Why Did ArriVent BioPharma (AVBP) Move Today? - sahmcapital.com
ArriVent (AVBP) Trading: Posts a 2.95% Loss to $28.26 in the Current Update; Levels: Price Remains Between $26.85 Support and $29.67 ResistanceIV Spike - vinanet.vn
109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd. - MarketBeat
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Moomoo
HC Wainwright Issues Pessimistic Forecast for AVBP Earnings - MarketBeat
What is HC Wainwright's Estimate for AVBP FY2027 Earnings? - MarketBeat
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47 - Moomoo
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal - Sahm
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook - Investing.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - MarketBeat
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook By Investing.com - Investing.com Canada
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash - MyChesCo
ArriVent Biopharma price target lowered to $40 from $43 at Citi - TipRanks
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Technical Reactions to AVBP Trends in Macro Strategies - Stock Traders Daily
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50 - Moomoo
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC - AllSci
ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - MarketBeat
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks
ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
ArriVent inks China partnership for ARR-002 development - TipRanks
2.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):